Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Withdrawn due to difficulties in to recruiting due to competing studies, changing treatment practices, unavailability of eligible study population

Conditions

Interventions

Sponsor

GlaxoSmithKline